GlassScriptPhysician profile
Raymond Lobins
NPI 1356391064
$21,928.50
in general payments reported to CMS, 2019-2025
45 companies · $1,321 in 2025
The $1,321 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $254 · 2021: $791 · 2022: $1,242 · 2023: $2,540 · 2024: $5,522 · 2025: $1,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,910 · Food and Beverage: $2,410 · Travel and Lodging: $994 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,910.00 |
| Food and Beverage | $2,410.48 |
| Travel and Lodging | $994.01 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,194.14 | 2019-2022 | |
| Gilead Sciences, INC. | $5,028.45 | 2021-2025 | Trodelvy |
| Abbvie INC. | $2,505.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $511.85 | 2019-2025 | Imfinzi, Enhertu |
| Celgene Corporation | $434.64 | 2022-2025 | Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $430.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $331.65 | 2019-2025 | Opdivo, Krazati |
| Amgen INC. | $274.31 | 2019-2020 | |
| Daiichi Sankyo INC. | $221.64 | 2024-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $188.98 | 2019-2024 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $155.65 | 2019-2025 | Welireg, Keytruda |
| Genzyme Corporation | $144.39 | 2019-2024 | |
| Pfizer INC. | $138.91 | 2019-2025 | |
| Beigene USA, INC. | $122.29 | 2020-2021 | |
| Lilly USA, LLC | $120.46 | 2021 |
Show all 43 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Lobins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.